Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Please note, this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Multiple Myeloma and Bone Disease
Diagnosing Bone Disease
Impact of Bone Disease
Pathophysiology of Bone Disease in MM
Bone-Modifying Agents
Myeloma IX Trial Study Design
Myeloma IX Trial Impact of ZA on Survival
Myeloma IX Trial Impact of ZA on SREs
Non-Inferiority Study of Denosumab vs ZA Study Design
Non-Inferiority Study of Denosumab vs ZA SREs and PFS
Key Treatment-Emergent Adverse Events
Reversibility of Bone Modifying Agents
ASCO and NCCN Guidelines for Treatment With BMAs
Treatment Duration With Bisphosphonates
Treatment Duration With Bisphosphonates (cont)
Managing AEs Induced by BMAs Expert Opinion
Key Takeaways
Abbreviations
Abbreviations (cont)
Abbreviations (cont)